Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Retained Earnings (2019 - 2025)

Immunocore Holdings' Retained Earnings history spans 4 years, with the latest figure at -$831.3 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 4.46% year-over-year to -$831.3 million; the TTM value through Dec 2025 reached -$831.3 million, down 4.46%, while the annual FY2025 figure was -$831.3 million, 4.46% down from the prior year.
  • Retained Earnings for Q4 2025 was -$831.3 million at Immunocore Holdings, down from -$30.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$26.6 million in Q2 2025 and bottomed at -$831.3 million in Q4 2025.
  • The 4-year median for Retained Earnings is -$399.7 million (2022), against an average of -$410.4 million.
  • The largest annual shift saw Retained Earnings plummeted 1262.05% in 2023 before it surged 96.59% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$54.7 million in 2022, then tumbled by 1262.05% to -$744.7 million in 2023, then fell by 6.86% to -$795.8 million in 2024, then dropped by 4.46% to -$831.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Retained Earnings are -$831.3 million (Q4 2025), -$30.0 million (Q3 2025), and -$26.6 million (Q2 2025).